person · Reporting owner
Longsworth Todd Christopher
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NovoCure LtdNVCR · Entity 4494 | General Counsel | March 08, 2022 | March 09, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NovoCure Ltd
Report date March 08, 2022 · Filed March 09, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 62,462 |
Reported balance
After 2022-03-08 transaction · row 1
1 source rowRow 1 · 2022-03-08 · Sale · Disposed 2,339 · Balance 62,462 F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units listed. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units listed. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 08, 2022 Filed Mar 9, 2022 16:50 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 2,339 | $70.10 | $163,963.90 |
DisclosureSEC source: 0001645113-22-000025 · wf-form4_164686256918260.xml · nonDerivative · entry 1 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,462 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units listed. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 04, 2022 Filed Mar 7, 2022 18:28 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,973 | $70.41 | $138,913.01 |
DisclosureSEC source: 0001645113-22-000023 · wf-form4_164669568882280.xml · nonDerivative · entry 2 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,801 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 03, 2022 Filed Mar 7, 2022 18:28 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOptions to Buy Ordinary Shares · Derivative | 6,106 | $80.59 Strike: $80.59 | $492,082.54 |
DisclosureSEC source: 0001645113-22-000023 · wf-form4_164669568882280.xml · derivative · entry 3 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,106 Underlying: Ordinary Shares · 6,106 shares Expires 2032-02-29 F2 · shares: Options to buy 6,106 ordinary shares will vest and become exercisable in equal installments on each of March 1, 2023 and 2024, subject to the reporting person's continued employment through such dates. Read SEC document |
| March 03, 2022 Filed Mar 7, 2022 18:28 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,094 | $74.50 | $81,500.81 |
DisclosureSEC source: 0001645113-22-000023 · wf-form4_164669568882280.xml · nonDerivative · entry 1 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,774 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 17:26 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 154 | $137.12 | $21,116.79 |
DisclosureSEC source: 0001645113-21-000082 · wf-form4_162577957572435.xml · nonDerivative · entry 1 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,868 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2021 through June 30, 2021. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 30, 2021. Read SEC document |
| March 08, 2021 Filed Mar 10, 2021 16:08 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleRestricted Share Units | 2,404 | $130.81 | $314,457.62 |
DisclosureSEC source: 0001645113-21-000045 · wf-form4_161541050375020.xml · nonDerivative · entry 1 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,714 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted share units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 16:25 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleRestricted Share Units | 3,084 | $137.55 | $424,216.54 |
DisclosureSEC source: 0001645113-21-000039 · wf-form4_161523872602441.xml · nonDerivative · entry 1 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,118 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units vested on March 3, 2021. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 17:44 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOptions to Buy Ordinary Shares · Derivative | 19,004 | $0.00 Strike: $153.09 | $0.00 |
DisclosureSEC source: 0001645113-21-000026 · wf-form4_161489786798435.xml · derivative · entry 3 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,004 Underlying: Ordinary Shares · 19,004 shares Expires 2031-03-01 F3 · derivative.exercise_date: Options to buy 19,004 ordinary shares will vest and become exercisable in equal installments on each of March 2, 2022, 2023, 2024 and 2025, subject to the reporting person's continued employment through such dates. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 17:44 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantRestricted Share Units | 10,342 | $0.00 | $0.00 |
DisclosureSEC source: 0001645113-21-000026 · wf-form4_161489786798435.xml · nonDerivative · entry 2 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,202 F2 · shares: Represents restricted share units that are scheduled to vest in equal installments on each of March 2, 2022, 2023 and 2024, subject to the reporting person's continued employment through such dates. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 17:44 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleRestricted Share Units | 2,355 | $152.05 | $358,084.82 |
DisclosureSEC source: 0001645113-21-000026 · wf-form4_161489786798435.xml · nonDerivative · entry 1 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,860 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units vested on February 27, 2021. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| February 27, 2021 Filed Mar 2, 2021 16:15 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionRestricted Stock Units · Derivative | 5,555 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001645113-21-000023 · wf-form4_161471970637754.xml · derivative · entry 2 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 5,555 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.expiration_date: Fully vested as of the date hereof. Read SEC document |
| February 27, 2021 Filed Mar 2, 2021 16:15 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 5,555 | $149.10 | $828,250.50 |
DisclosureSEC source: 0001645113-21-000023 · wf-form4_161471970637754.xml · nonDerivative · entry 1 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,215 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 15, 2021 Filed Jan 19, 2021 17:00 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 36,396 | $0.00 Strike: $14.37 | $0.00 |
DisclosureSEC source: 0001645113-21-000008 · wf-form4_161109361209620.xml · derivative · entry 26 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 36,396 shares Expires 2025-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F25 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| January 15, 2021 Filed Jan 19, 2021 17:00 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,200 | $179.30 | $215,161.20 |
DisclosureSEC source: 0001645113-21-000008 · wf-form4_161109361209620.xml · nonDerivative · entry 25 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,660 F24 · price: On January 15, 2021, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Longsworth, Mr. Longsworth sold 1,200 shares in multiple trades at prices ranging from $179.10 to $179.60. The price reported above reflects the weighted average sale price. Mr. Longsworth hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 15, 2021 Filed Jan 19, 2021 17:00 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 900 | $178.50 | $160,648.20 |
DisclosureSEC source: 0001645113-21-000008 · wf-form4_161109361209620.xml · nonDerivative · entry 24 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,860 F23 · price: On January 15, 2021, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Longsworth, Mr. Longsworth sold 900 shares in multiple trades at prices ranging from $178.10 to $178.98. The price reported above reflects the weighted average sale price. Mr. Longsworth hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 15, 2021 Filed Jan 19, 2021 17:00 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 2,841 | $177.33 | $503,797.37 |
DisclosureSEC source: 0001645113-21-000008 · wf-form4_161109361209620.xml · nonDerivative · entry 23 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,760 F22 · price: On January 15, 2021, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Longsworth, Mr. Longsworth sold 2,841 shares in multiple trades at prices ranging from $177.02 to $177.76. The price reported above reflects the weighted average sale price. Mr. Longsworth hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 15, 2021 Filed Jan 19, 2021 17:00 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 400 | $176.22 | $70,486.00 |
DisclosureSEC source: 0001645113-21-000008 · wf-form4_161109361209620.xml · nonDerivative · entry 22 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,601 F21 · price: On January 15, 2021, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Longsworth, Mr. Longsworth sold 400 shares in multiple trades at prices ranging from $175.93 to $176.62. The price reported above reflects the weighted average sale price. Mr. Longsworth hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 15, 2021 Filed Jan 19, 2021 17:00 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 2,200 | $175.28 | $385,613.80 |
DisclosureSEC source: 0001645113-21-000008 · wf-form4_161109361209620.xml · nonDerivative · entry 21 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,001 F20 · price: On January 15, 2021, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Longsworth, Mr. Longsworth sold 2,200 shares in multiple trades at prices ranging from $174.92 to $175.64. The price reported above reflects the weighted average sale price. Mr. Longsworth hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 15, 2021 Filed Jan 19, 2021 17:00 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 2,502 | $174.06 | $435,505.63 |
DisclosureSEC source: 0001645113-21-000008 · wf-form4_161109361209620.xml · nonDerivative · entry 20 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,201 F19 · price: On January 15, 2021, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Longsworth, Mr. Longsworth sold 2,502 shares in multiple trades at prices ranging from $173.72 to $174.69. The price reported above reflects the weighted average sale price. Mr. Longsworth hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 15, 2021 Filed Jan 19, 2021 17:00 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,700 | $173.10 | $294,270.00 |
DisclosureSEC source: 0001645113-21-000008 · wf-form4_161109361209620.xml · nonDerivative · entry 19 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,703 F18 · price: On January 15, 2021, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Longsworth, Mr. Longsworth sold 1,700 shares in multiple trades at prices ranging from $172.69 to $173.65. The price reported above reflects the weighted average sale price. Mr. Longsworth hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 15, 2021 Filed Jan 19, 2021 17:00 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 11,985 | $171.90 | $2,060,257.46 |
DisclosureSEC source: 0001645113-21-000008 · wf-form4_161109361209620.xml · nonDerivative · entry 18 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,403 F17 · price: On January 15, 2021, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Longsworth, Mr. Longsworth sold 11,985 shares in multiple trades at prices ranging from $171.58 to $172.51. The price reported above reflects the weighted average sale price. Mr. Longsworth hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 15, 2021 Filed Jan 19, 2021 17:00 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 4,826 | $171.32 | $826,780.67 |
DisclosureSEC source: 0001645113-21-000008 · wf-form4_161109361209620.xml · nonDerivative · entry 17 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,388 F16 · price: On January 15, 2021, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Longsworth, Mr. Longsworth sold 4,826 shares in multiple trades at prices ranging from $170.58 to $171.57. The price reported above reflects the weighted average sale price. Mr. Longsworth hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 15, 2021 Filed Jan 19, 2021 17:00 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 2,542 | $169.93 | $431,969.69 |
DisclosureSEC source: 0001645113-21-000008 · wf-form4_161109361209620.xml · nonDerivative · entry 16 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,214 F15 · price: On January 15, 2021, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Longsworth, Mr. Longsworth sold 2,542 shares in multiple trades at prices ranging from $169.55 to $170.51. The price reported above reflects the weighted average sale price. Mr. Longsworth hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 15, 2021 Filed Jan 19, 2021 17:00 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,800 | $169.19 | $304,549.20 |
DisclosureSEC source: 0001645113-21-000008 · wf-form4_161109361209620.xml · nonDerivative · entry 15 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,756 F14 · price: On January 15, 2021, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Longsworth, Mr. Longsworth sold 1,800 shares in multiple trades at prices ranging from $168.54 to $169.52. The price reported above reflects the weighted average sale price. Mr. Longsworth hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 15, 2021 Filed Jan 19, 2021 17:00 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 3,500 | $167.77 | $587,209.00 |
DisclosureSEC source: 0001645113-21-000008 · wf-form4_161109361209620.xml · nonDerivative · entry 14 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,556 F13 · price: On January 15, 2021, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Longsworth, Mr. Longsworth sold 3,500 shares in multiple trades at prices ranging from $167.41 to $168.18. The price reported above reflects the weighted average sale price. Mr. Longsworth hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 15, 2021 Filed Jan 19, 2021 17:00 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 900 | $179.37 | $161,431.20 |
DisclosureSEC source: 0001645113-21-000008 · wf-form4_161109361209620.xml · nonDerivative · entry 13 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,056 F12 · price: On January 15, 2021, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Longsworth, Mr. Longsworth sold 900 shares in multiple trades at prices ranging from $179.22 to $179.70. The price reported above reflects the weighted average sale price. Mr. Longsworth hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 15, 2021 Filed Jan 19, 2021 17:00 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,000 | $178.68 | $178,675.00 |
DisclosureSEC source: 0001645113-21-000008 · wf-form4_161109361209620.xml · nonDerivative · entry 12 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,956 F11 · price: On January 15, 2021, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Longsworth, Mr. Longsworth sold 1,000 shares in multiple trades at prices ranging from $178.16 to $179.08. The price reported above reflects the weighted average sale price. Mr. Longsworth hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 15, 2021 Filed Jan 19, 2021 17:00 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 2,200 | $177.31 | $390,071.00 |
DisclosureSEC source: 0001645113-21-000008 · wf-form4_161109361209620.xml · nonDerivative · entry 11 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,956 F10 · price: On January 15, 2021, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Longsworth, Mr. Longsworth sold 2,200 shares in multiple trades at prices ranging from $177.02 to $177.72. The price reported above reflects the weighted average sale price. Mr. Longsworth hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 15, 2021 Filed Jan 19, 2021 17:00 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 400 | $175.98 | $70,392.40 |
DisclosureSEC source: 0001645113-21-000008 · wf-form4_161109361209620.xml · nonDerivative · entry 10 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,156 F9 · price: On January 15, 2021, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Longsworth, Mr. Longsworth sold 400 shares in multiple trades at prices ranging from $175.69 to $176.38. The price reported above reflects the weighted average sale price. Mr. Longsworth hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 15, 2021 Filed Jan 19, 2021 17:00 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,700 | $175.14 | $297,731.20 |
DisclosureSEC source: 0001645113-21-000008 · wf-form4_161109361209620.xml · nonDerivative · entry 9 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,556 F8 · price: On January 15, 2021, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Longsworth, Mr. Longsworth sold 1,700 shares in multiple trades at prices ranging from $174.67 to $175.64. The price reported above reflects the weighted average sale price. Mr. Longsworth hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 15, 2021 Filed Jan 19, 2021 17:00 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,600 | $173.88 | $278,204.80 |
DisclosureSEC source: 0001645113-21-000008 · wf-form4_161109361209620.xml · nonDerivative · entry 8 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,256 F7 · price: On January 15, 2021, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Longsworth, Mr. Longsworth sold 1,600 shares in multiple trades at prices ranging from $173.55 to $174.40. The price reported above reflects the weighted average sale price. Mr. Longsworth hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 15, 2021 Filed Jan 19, 2021 17:00 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,300 | $172.95 | $224,837.60 |
DisclosureSEC source: 0001645113-21-000008 · wf-form4_161109361209620.xml · nonDerivative · entry 7 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,856 F6 · price: On January 15, 2021, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Longsworth, Mr. Longsworth sold 1,300 shares in multiple trades at prices ranging from $172.51 to $173.20. The price reported above reflects the weighted average sale price. Mr. Longsworth hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 15, 2021 Filed Jan 19, 2021 17:00 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 10,110 | $171.86 | $1,737,494.49 |
DisclosureSEC source: 0001645113-21-000008 · wf-form4_161109361209620.xml · nonDerivative · entry 6 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,156 F5 · price: On January 15, 2021, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Longsworth, Mr. Longsworth sold 10,110 shares in multiple trades at prices ranging from $171.50 to $172.40. The price reported above reflects the weighted average sale price. Mr. Longsworth hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 15, 2021 Filed Jan 19, 2021 17:00 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 2,761 | $171.18 | $472,639.02 |
DisclosureSEC source: 0001645113-21-000008 · wf-form4_161109361209620.xml · nonDerivative · entry 5 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,266 F4 · price: On January 15, 2021, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Longsworth, Mr. Longsworth sold 2,761 shares in multiple trades at prices ranging from $170.50 to $171.49. The price reported above reflects the weighted average sale price. Mr. Longsworth hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 15, 2021 Filed Jan 19, 2021 17:00 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 2,148 | $169.76 | $364,644.48 |
DisclosureSEC source: 0001645113-21-000008 · wf-form4_161109361209620.xml · nonDerivative · entry 4 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,027 F3 · price: On January 15, 2021, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Longsworth, Mr. Longsworth sold 2,148 shares in multiple trades at prices ranging from $169.46 to $170.27. The price reported above reflects the weighted average sale price. Mr. Longsworth hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 15, 2021 Filed Jan 19, 2021 17:00 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 800 | $168.80 | $135,043.20 |
DisclosureSEC source: 0001645113-21-000008 · wf-form4_161109361209620.xml · nonDerivative · entry 3 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,175 F2 · price: On January 15, 2021, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Longsworth, Mr. Longsworth sold 800 shares in multiple trades at prices ranging from $168.44 to $169.25. The price reported above reflects the weighted average sale price. Mr. Longsworth hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 15, 2021 Filed Jan 19, 2021 17:00 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 2,499 | $167.76 | $419,234.74 |
DisclosureSEC source: 0001645113-21-000008 · wf-form4_161109361209620.xml · nonDerivative · entry 2 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,975 F1 · price: On January 15, 2021, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Longsworth, Mr. Longsworth sold 2,499 shares in multiple trades at prices ranging from $167.41 to $168.18. The price reported above reflects the weighted average sale price. Mr. Longsworth hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 15, 2021 Filed Jan 19, 2021 17:00 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 36,396 | $14.37 | $523,010.52 |
DisclosureSEC source: 0001645113-21-000008 · wf-form4_161109361209620.xml · nonDerivative · entry 1 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,474 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 07, 2020 Filed Jul 8, 2020 16:24 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 325 | $50.41 | $16,381.63 |
DisclosureSEC source: 0001645113-20-000095 · wf-form4_159423984492801.xml · nonDerivative · entry 1 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,078 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2020 through June 30, 2020. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 30, 2020. Read SEC document |
| March 06, 2020 Filed Mar 10, 2020 16:15 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleRestricted Share Units | 2,499 | $69.53 | $173,765.47 |
DisclosureSEC source: 0001645113-20-000047 · wf-form4_158387131442466.xml · nonDerivative · entry 1 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,753 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units vested on March 5, 2020. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 03, 2020 Filed Mar 5, 2020 18:50 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOptions to Buy Ordinary Shares · Derivative | 37,058 | $0.00 Strike: $69.37 | $0.00 |
DisclosureSEC source: 0001645113-20-000038 · wf-form4_158345218296520.xml · derivative · entry 2 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,058 Underlying: Ordinary Shares · 37,058 shares Expires 2030-03-02 F2 · derivative.exercise_date: Options to buy 37,058 ordinary shares will vest and become exercisable in equal installments on each of March 3, 2021, 2022, 2023 and 2024, subject to the reporting person's continued employment through such dates. Read SEC document |
| March 03, 2020 Filed Mar 5, 2020 18:50 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantRestricted Share Units | 19,220 | $0.00 | $0.00 |
DisclosureSEC source: 0001645113-20-000038 · wf-form4_158345218296520.xml · nonDerivative · entry 1 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,252 F1 · shares: Represents restricted share units that are scheduled to vest on March 3, 2021, 2022 and 2023, subject to the reporting person's continued employment through such dates. Read SEC document |
| February 28, 2020 Filed Mar 2, 2020 17:11 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 2,643 | $72.22 | $190,864.25 |
DisclosureSEC source: 0001645113-20-000030 · wf-form4_158318709905785.xml · nonDerivative · entry 2 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,032 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| February 27, 2020 Filed Mar 2, 2020 17:11 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionRestricted Stock Units · Derivative | 5,556 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001645113-20-000030 · wf-form4_158318709905785.xml · derivative · entry 3 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,555 Underlying: Ordinary Shares · 5,556 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.expiration_date: Fully vested as of the date hereof. Read SEC document |
| February 27, 2020 Filed Mar 2, 2020 17:11 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 5,556 | $79.45 | $441,424.20 |
DisclosureSEC source: 0001645113-20-000030 · wf-form4_158318709905785.xml · nonDerivative · entry 1 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,675 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 17:14 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 8,482 | $81.16 | $688,365.19 |
DisclosureSEC source: 0001645113-20-000013 · wf-form4_158275523372813.xml · nonDerivative · entry 2 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,119 F1 · security: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. The sale is mandated by the Issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| February 24, 2020 Filed Feb 26, 2020 17:14 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionRestricted Stock Units · Derivative | 21,666 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001645113-20-000013 · wf-form4_158275523372813.xml · derivative · entry 3 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 21,666 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.expiration_date: Fully vested as of the date hereof. Read SEC document |
| February 24, 2020 Filed Feb 26, 2020 17:14 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 21,666 | $88.26 | $1,912,241.16 |
DisclosureSEC source: 0001645113-20-000013 · wf-form4_158275523372813.xml · nonDerivative · entry 1 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,601 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 08, 2020 Filed Jan 13, 2020 16:09 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 35 | $52.58 | $1,840.34 |
DisclosureSEC source: 0001645113-20-000005 · wf-form4_157894975363044.xml · nonDerivative · entry 1 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,935 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of July 1, 2019 through December 31, 2019. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on July 1, 2019. Read SEC document |
| September 03, 2019 Filed Sep 5, 2019 16:09 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 30,414 | $0.00 Strike: $21.15 | $0.00 |
DisclosureSEC source: 0001209191-19-048481 · doc4.xml · derivative · entry 24 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,513 Underlying: Ordinary Shares · 30,414 shares Expires 2028-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F18 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.